Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Autologous stem cell transplantation in adults with atypical teratoid rhabdoid tumor: a case report and review

Griffith-Linsley J., Bell WR., Cohen-Gadol A., Donegan D., Richardson A., Robertson M.

Prospective Study, published in CNS Oncol (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
CNS Oncol (2024)
Reported sample size
—
Source database
Europe PMC
PMID
39039959
PMCID
PMC11285279
DOI
10.1080/20450907.2024.2375960
Citations
1

Abstract (original English)

Aim: Atypical teratoid rhabdoid tumor (ATRT) is a rare and highly aggressive primary CNS neoplasm, predominantly observed in children. The use of autologous stem cell transplantation (ASCT) in pediatric ATRT has shown promise; however, its utility in adult ATRT remains unclear. Patients & methods: This study presents the case of an adult patient with ATRT who is in remission after ASCT and reviews the literature on ASCT in adults with ATRT. Four cases of ATRT in adults who underwent ASCT were identified, with pertinent data summarized. Results: All five patients survived longer than the historical average survival rate, four of whom had no clinical or radiographic evidence of disease at the final follow-up. Conclusion: Based on limited data, there may be a role for ASCT in the treatment of adults with ATRT.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansRhabdoid TumorTeratomaBrain NeoplasmsStem Cell TransplantationTransplantation, AutologousAdult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.